

Ludwig Scientist(s)	Affiliation(s)	Session Time	Location	Session Type	Session Title	Presentation/Abstract Title & Time			
	Saturday, April 1								
Cigall Kadoch	Ludwig Harvard	9:00 - 9:25am	Room 150, Level 1, Washington Convention Center	Educational Session	Epigenetics and Cancer	ATP-dependent chromatin remodeling complexes in human cancer			
Alan D'Andrea	Ludwig Harvard	8:00 - 10:00am	Room 206, Level 2, Washington Convention Center	Educational Session	Synthetic Lethality for treating DNA Repair Defective Human Cancer	8:30 - 8:55am: Synthetic lethality for Fanconi anemia/BRCA pathway defects			
Ash Alizadeh	Ludwig Stanford	11:45 - 12:10pm	Ballroom A-B, Level 3, Washington Convention Center	Educational Session	Integrating Genomic Analyses of Immunotherapy	Infiltrating immune cell signatures and genomic determinants of immune recognition in diverse tumors			
Anthony Letai	Ludwig Harvard	3:15 - 5:15 pm	Room 145, Level 1, Washington Convention Center	Educational Session	Functional Diagnostics for Precision Cancer Care	4:45 - 5:10pm: Dynamic BH3 profiling measures primary cancer cell response to drugs without prolonged ex vivo culture			
Anthony Letai	Ludwig Harvard	1:00 - 3:00pm	Room 150, Level 1, Washington Convention Center	Educational Session	Cell Death Programs in Cancer Biology and Therapy	1:30 - 1:55pm: Mitochondria expose cancer cell vulnerabilities			

<sup>\*</sup>scientist is lead author

<sup>\*\*</sup>scientist is senior author



	Sunday, April 2							
Luis Diaz, Kenneth Kinzler, Nickolas Papadopoulos, Bert Vogelstein	Ludwig Johns Hopkins	8:00 - 9:00am	Hall D-E, Level 2, Washington Convention Center	Award Ceremony	Eleventh Annual AACR Team Science Award	N/A		
Bert Vogelstein	Ludwig Johns Hopkins	11:00 - 11:30am	Hall D-E, Level 2, Washington Convention Center	Opening Plenary	The Road to Cancer Cures—Discover, Predict, Prevent, and Treat	Earlier detection as a key to lower cancer death rates		
Hao Liu*, Kamila Naxerova, Rakesh Jain**	Ludwig Harvard	1:00 - 5:00pm	Section 44	Poster Session	Tumor Microenvironment 1	Use of angiotensin system inhibitors is associated with longer overall survival in pancreatic ductal adenocarcinoma patients who underwent pancreatectomy		
Michelle Monje Deisseroth	Ludwig Stanford	1:00 - 2:45pm	Room 151, Level 1, Washington Convention Center	Recent Advances in Organ Site Research	Pediatric Brain Tumors: Developmental Connections to Disease Pathogenesis	1:30 - 1:55pm: Neuronal activity drives pediatric high- grade glioma growth		
Sameer Chopra*, Mario Niepel, Marc Hafner, Peter Sorger**	Ludwig Harvard	1:00 - 5:00pm	Section 6, poster board 9	Poster Session	Targeting the PI3K Pathway	Exploiting replicative vulnerabilities to counter incomplete responses to PI3K/Akt/mTOR inhibition		

<sup>\*</sup>scientist is lead author

<sup>\*\*</sup>scientist is senior author

Crystal Mackall*	Ludwig Stanford	1:00 - 5:00pm	Section 29, poster board 2	Poster Session	Childhood Cancer Clinical Translational Research	GPC2 is an oncogene and immunotherapeutic target in high-risk neuroblastoma
Sadna Budhu*, Roberta Zappasodi, Rachel Giese, Luis Campesato, Jedd Wolchok, Taha Merghoub**	Ludwig MSK	1:00 - 5:00pm	Section 25, poster board 8	Poster Session	Checkpoints 1	Phosphatidylserine targeting antibody in combination with tumor radiation and immune checkpoint blockade promotes anti-tumor activity in mouse B16 melanoma
Stephen Kron**	Ludwig Chicago	1:00- 5:00pm	Section 25, poster board 4	Poster Session	Checkpoints 1	Transparent tumor tomography (T3): 3D spatial immunoanalysis for PD-L1 immune checkpoint blockade therapy
Michael Clarke*	Ludwig Stanford	1:00 - 5:00pm	Section 4, poster board 2	Poster Session	Gene Expression of Drug Resistance	E2F4/p107 complex regulates chemotherapy resistance in human colorectal cancer stem cells
Cigall Kadoch** (session chair)	Ludwig Harvard	3:00 - 5:00pm	Room 147, Level 1, Washington Convention Center	Minisymposium	Chromatin Structure and Function	3:05 - 3:20pm: BRD9 defines a novel mammalian SWI/SNF (BAF) complex configuration which supports proliferation in AML

<sup>\*</sup>scientist is lead author

<sup>\*\*</sup>scientist is senior author

Ash Alizadeh**, Maximilian Diehn**	Ludwig Stanford	3:00 - 5:00pm	Room 144, Level 1, Washington Convention Center	Minisymposium	Animal Models of Human Oncogenesis	Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance
Roberta Zappasodi*, Yanyun Li, Mohsen Abu- Akeel, Jingjing Qi, Philip Wong, Michael Postow, Margaret Callahan, Jedd Wolchok, Taha Merghoub**	Ludwig MSK; Ludwig New York	3:00 - 5:00pm	I///achinatan	Clinical Trials Plenary Session	Immuno-oncology Biomarkers in Clinical Trials	3:36 - 3:55pm: Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial
Marc Hafner*, Mario Niepel, Peter Sorger**	Ludwig Harvard	3:00 - 5:00pm	Room 151, Level 1, Washington Convention Center	Minisymposium	Computational Cancer Biology	3:20 - 3:35pm: Improving pre- clinical cancer pharmacogenomics with novel drug sensitivity metrics based on growth rate inhibition
Kenneth Kinzler	Ludwig Johns Hopkins	3:30 - 4:30pm	I I DESTAT B. EVNINIT	Exhibitor Spotlight Presentation	Sysmex Inostics: The OncoBEAM™ Advantage: Using cfDNA Liquid Biopsy Assays in Research and Clinical Practice	The Evolution of Digital Genomics and Liquid Biopsies
Jedd Wolchok	Ludwig MSK	6:15 - 6:30pm	Independence Ballroom A-D, Meeting Level 4, Marriott Marquis DC	Town Hall	Cancer Immunology Working Group (CIMM) Town Hall Meeting and Reception	Remarks: CIMM Chair-elect

<sup>\*</sup>scientist is lead author

<sup>\*\*</sup>scientist is senior author



	Monday, April 3								
Crystal Mackall**	Ludwig Stanford	8:00 - 12:00pm	Section 26, poster board 5	Poster Session	Cytokines: The First Modern Immunotherapies	Inhibition of the novel therapeutic target pregnancy associated plasma protein A (PAPP-A) in Ewing sarcoma enhances efficacy of IGF1R targeting in vivo			
Ralph Weichselbaum**	Ludwig Chicago	8:00 - 12:00pm	Section 39, poster board 19	Poster Session	Imaging for Cancer Diagnosis and Image- Guided Therapy	First demonstration that hypoxia targeting with radiation improves tumor control in a mammal tumor model			
Jia-Ren Lin*, Peter Sorger**	Ludwig Harvard	8:00 - 12:00pm	Section 29, poster board 24	Poster Session	Adaptive Immunity to Cancer	Slide-based multi-parametric immunophenotyping of human blood samples by cyclic immunofluorescence using the Accucyte-CyteFinder system			
Adam Palmer*, Peter Sorger**	Ludwig Harvard	8:00 - 12:00pm	Section 1, poster board 16	Poster Session	Combination Strategies: Novel Agents and Standard Therapies	Benefit from combination cancer therapy arising from patient-to-patient variability rather than additive or synergistic drug action			

<sup>\*</sup>scientist is lead author

<sup>\*\*</sup>scientist is senior author

Gregory Baker*, Peter Sorger**	Ludwig Harvard	8:00 - 12:00pm	Section 28, poster board 26	Poster Session	Tumor Models and Assays	A flow-based immunoprofiling strategy for interrogating system-wide leukocyte composition in response to glioblastoma
Daniel Hirschhorn- Cymerman*, Sadna Budhu, Zhong Hong, Yia Yang, Jedd Wolchok, Taha Merghoub*	Ludwig MSK	8:00 - 12:00pm	Section 27, poster board 29	Poster Session	Tumor Microenvironment and Checkpoints	Targeting phosphatidylserine in combination with adoptive T cell transfer eliminates advanced tumors without off-target toxicities in a melanoma preclinical model
Crystal Mackall	Ludwig Stanford	8:15 - 10:15am	Hall D-E, Level 2, Washington Convention Center	Plenary Session	The Immune System and Cancer	9:15 - 9:45am: Genetically engineered T cells for cancer
Joan Brugge (session chair)	Ludwig Harvard	1:00 - 2:45pm	East Salon A-B, Level 1, Washington Convention Center	Major Symposium	Adaptive Response to Therapy	1:05 - 1:30pm: Systems analysis of adaptive responses in patient-derived ovarian cancer xenografts to identify combination therapies and predictive biomarkers
Arlene Sharpe	Ludwig Harvard	1:00 - 2:45pm	Ballroom A-B, Level 3, Washington Convention Center	Major Symposium	Genetic Influences on Anticancer Immunity	1:35 - 2:00pm: The multifaceted functions of the PD-1 pathway

<sup>\*</sup>scientist is lead author

<sup>\*\*</sup>scientist is senior author

Caitlin Mills*, Marc Hafner, Peter Sorger**	Ludwig Harvard	1:00 - 5:00pm	Section 15	Poster Session	Cell Growth Signaling Pathways 5	Systematic characterization of kinase inhibitors reveals heterogeneity in responses by class and cell line
Benjamin Izar*, Asaf Rotem, Aviv Regev**	Ludwig Harvard; Ludwig MIT	3:00 - 5:00pm	Room 145, Level 1, Washington Convention Center	Minisymposium	Canomics Dissecting	Dissecting treatment resistance in patients with ovarian cancer and PDX-models using single-cell RNA-sequencing
Maximilian Diehn	Ludwig Stanford	5:00 - 7:00pm	Liberty Ballroom, Meeting Level 4, Marriott Marquis DC	Town Hall	Radiation Science and Medicine Working Group Town Hall Meeting and Networking Reception	N/A
Robert Weinberg (session chair)	Ludwig MIT	5:00 - 6:30pm	Ballroom A-B, Level 3, Washington Convention Center	Special Session		5:15 - 5:35pm: Emerging Hallmarks
Kornelia Polyak (AACR Annual Meeting Program Chair)	Ludwig Harvard	5:00 - 6:30pm	Room 202, Level 2, Washington Convention Center	Special Session	Session: Clinical	5:50 - 6:10pm: Heterogeneity in breast tumors: More than the sum of its parts

<sup>\*</sup>scientist is lead author

<sup>\*\*</sup>scientist is senior author



	Tuesday, April 4								
Myles Brown	Ludwig Harvard	7:00 - 8:00am	Room 206, Level 2, Washington Convention Center	Meet the Expert	Elucidating Mechanisms to Overcome Endocrine Therapy Resistance	N/A			
Rakesh Jain	Ludwig Harvard	7:00 - 8:00am	East Salon C, Level 1, Washington Convention Center	Meet the Expert	Reprogramming the Tumor Microenvironment using Angiotensin System Inhibitors to Enhance Cancer Treatment: Bench to Bedside	N/A			
David Schaer, Taha Merghoub, Gerd Ritter	Ludwig MSK; Ludwig New York	8:00 - 12:00pm	Section 26	Poster Session	BITES Bispecifics and Checkpoints	AGEN1884, an IgG1 anti- CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model			
Taha Merghoub, Roberta Zappasodi, Gerd Ritter, David Schaer	Ludwig MSK; Ludwig New York	8:00 - 12:00pm	Section 26	Poster Session	BITES Bispecifics and Checkpoints	INCAGN1876, a unique GITR agonist antibody that facilitates GITR oligomerization			
Michael Postow, Jedd Wolchok**	Ludwig MSK	8:00 - 12:00pm	Section 33	Poster Session	Phase I Clinical Trials	IPI-549-01: A Phase 1/1b, First- in-Human Study of IPI-549, a PI3K-Gamma Inhibitor, as Monotherapy and in Combination with Nivolumab in Patients with Advanced Solid Tumors			

<sup>\*</sup>scientist is lead author

<sup>\*\*</sup>scientist is senior author



Jonathan Cebon**	Ludwig Melbourne	8:00 - 12:00pm	Section 33	Poster Session	Phase I Clinical Trials	A phase I study of intralesional Bacillus Calmette-Guerin (BCG) followed by ipilimumab therapy in patients with advanced metastatic melanoma
Cigall Kadoch**	Ludwig Harvard	8:00 - 12:00pm	Section 38, poster board 13	Poster Session	Pediatric Cancer 2: Epigenetics and Stem Cells	SSX drives gain-of-function BAF complex chromatin affinity and genomic targeting in synovial sarcoma
Rakesh Jain**	Ludwig Harvard	8:00 - 12:00pm	Section 42, poster board 30	Poster Session	Tumor Microenvironment 5	Solid stress and elastic energy as measures of tumor mechanopathology
Myles Brown**	Ludwig Harvard	8:00 - 12:00pm	Section 16, poster board 7	Poster Session	Genomic Landscape of Breast, Prostate, Ovarian, Melanoma, and Thyroid Cancers	Reprogramming the estrogen signaling network is a potential mechanism for human breast tumorigenesis
Sanjiv Gambir*	Ludwig Stanford	8:00 - 12:00pm	Section 31, poster board 22	Poster Session	Liquid Biopsies 3: Circulating Tumor Cells, Extracellular Vesicles, and Exosomes	An intravascular magnetic wire for high-throughput in vivo enrichment of rare circulating cancer biomarkers
Sheheryar Kabraji*	Ludwig Harvard	8:00 - 12:00pm	Section 7	Poster Session	Novel Mechanisms 1	AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triplenegative breast cancer patients

<sup>\*</sup>scientist is lead author

<sup>\*\*</sup>scientist is senior author

Cigall Kadoch**	Ludwig Harvard	8:00 - 12:00pm	Section 38	Poster Session	Pediatric Cancer 2: Epigenetics and Stem Cells	SSX drives gain-of-function BAF complex chromatin affinity and genomic targeting in synovial sarcoma
Hendrik J. Kuiken*, Joan Brugge**	Ludwig Harvard	8:00 - 12:00pm	Section 41	Poster Session	Tumor Evolution and Heterogeneity 2	Characterization of functional heterogeneity and in vivo dynamics of clonal cell populations derived from the triple-negative breast cancer cell line MDA-MB-468
Isaac Harris, Daniel Stover, Karen Cichowski, Joan Brugge**	Ludwig Harvard	8:00 - 12:00pm	Section 20	Poster Session	Oxidative Stress, Autophagy, and Senescence	The TRPA1 Ca2+-permeable channel mediates a non-canonical redox adaptation in cancer cells
Matthew Vander Heiden	Ludwig MIT	10:30 - 12:30pm	Marquis Ballroom Salons 1-2, Meeting Level 2, Marriott Marquis DC	Special Session	SU2C Innovative Research Grant Poster Session	Defining the metabolic dependencies of tumors
Alan D'Andrea	Ludwig Harvard	10:30 - 12:15pm	Room 145, Level 1, Washington Convention Center	Major Symposium	Targeting DNA Damage/Repair in the Genome	11:05 - 11:30am: Novel mechanisms of PARP inhibitor resistance
Maximilian Diehn	Ludwig Stanford	10:30 - 12:15pm	Room 146, Level 1, Washington Convention Center	Major Symposium	Dharma Master Jiantai Symposium in Biomarkers: Liquid Biopsies - Emerging Technologies to Monitor Cancer Progression and Guide Treatment Selection	11:05 - 11:30am: Personalized cancer detection and monitoring via deep sequencing of circulating tumor DNA

<sup>\*</sup>scientist is lead author

<sup>\*\*</sup>scientist is senior author

Taha Merghoub, Daniel Hirschhorn-Cymerman, David Schaer, Gerd Ritter	Ludwig MSK; Ludwig New York	1:00 - 5:00pm	Section 30	Poster Session	Immunomodulatory Agents and Therapeutics	INCAGN1949, an anti-OX40 antibody with an optimal agonistic profile and the ability to selectively deplete intratumoral regulatory T cells
Ioannis Zervantonakis, Joan Brugge**	Ludwig Harvard	1:00 - 5:00pm	Section 2	Poster Session	and Approaches to Sensitize Cancer Cells	Combined MEK and BCL-2/XL inhibition as a potential drug combination for the treatment of high-grade serous ovarian cancer
Frank Slack	Ludwig Harvard	1:00 - 2:45pm	Room 152, Level 1, Washington Convention Center	Major Symposium	Dysregulation of MicroRNAs Leads to Target Therapy	1:30 - 1:50pm: MicroRNA- based therapeutics in cancer
Maximilian Diehn	Ludwig Stanford	2:30 - 3:30pm	I I Deater A. Exhibit	Exhibitor Spotlight Presentation	Roche Sequencing   Life Science: ctDNA Genomic Porfiling and Monitoring Assays – Performance and Reproducibility	N/A
Tyler Jacks**	Ludwig MIT	3:00 - 5:00pm	Room 206, Level 2, Washington Convention Center	Minisymposium	Resistance and Drug	Dissecting antigen-specific T- cell response in a novel mouse model of colon cancer
Rakesh Jain**	Ludwig Harvard	3:00 - 5:00pm	East Salon A-B, Level 1, Washington Convention Center	Minisymposium	Microenvironmental Cues in Immune Escape	The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

<sup>\*</sup>scientist is lead author

<sup>\*\*</sup>scientist is senior author

Isaac Harris*, Jennifer Endress, Joan Brugge**	Ludwig Harvard	3:00 - 5:00pm	Room 145, Level 1, Washington Convention Center	Minisymposium	Exploiting Metabolic Vulnerabilities to Treat Cancer	3:20 - 3:35pm: Understanding the vulnerabilities in cancer cells upon inhibition of glutathione synthesis
Peter Sorger	Ludwig Harvard	5:00 - 6:30pm	Room 147, Level 1, Washington Convention Center	Special Session	Advancing Cancer Therapy Using Data from the NIH LINCS Program	5:00 - 5:15pm: Introduction to the NIH LINCS Program
Caitlin Mills	Ludwig Harvard	5:00 - 6:30pm	Room 147, Level 1, Washington Convention Center	Special Session	Advancing Cancer Therapy Using Data from the NIH LINCS Program	5:30 - 5:45pm: Mining LINCS drug-response databases to identify novel activities of investigational breast cancer therapeutics
			Wednesday, Ap	oril 5		
Mohammad Fallahi*, Benjamin Izar, Jia-Ren Lin, Gregory Baker, Peter Sorger **	Ludwig Harvard	8:00 - 12:00pm	Convention Center, Halls A-C, Poster Section 23, poster board Number: 19	Poster Session	Systems Biology Approaches to Cancer Diagnostics and Disease Management	Single-cell analysis reveals an adaptive, transiently heritable, slowly-dividing, drug-resistant state inhibitable by drug combinations
Peter K. Sorger*, Marc Hafner, Mario Niepel, Caitlin Mills, Adam Palmer, Mohammed Fallahi Sichani**	Ludwig Harvard	8:00 - 12:00pm	Section 1, poster board 12	Poster Session	Anticancer Precision Clinical Pharmacology	New concepts for quantifying the benefits of mono and combination therapy in an era of big data
Cigall Kadoch**	Ludwig Harvard	8:00 - 12:00pm	Section 23, poster board 17	Poster Session	Systems Biology Approaches to Cancer Diagnostics and Disease Management	Using cancer dependency data to discover tumor suppressive and oncogenic functional modules
Sangeeta Bhatia**	Ludwig MIT	8:00 - 12:00pm	Section 3, poster board 4	Poster Session	Gene- and Vector-Based Therapy	Tumor penetrating RNA delivery for therapeutic benefit of pancreatic cancer

<sup>\*</sup>scientist is lead author

<sup>\*\*</sup>scientist is senior author

Cigall Kadoch**	Ludwig Harvard	8:00 - 12:00pm	Section 23, poster board 17	Poster Session	Approaches to Cancer Diagnostics and Disease	Using cancer dependency data to discover tumor suppressive and oncogenic functional modules
Franziska Michor	Ludwig Harvard	8:00 - 10:00am	Hall D-E, Level 2, Washington Convention Center	Plenary Session	IComputation and	9:30 - 10:00am: Mathematical modeling of cancer evolution
Sangeeta Bhatia	Ludwig MIT	8:30 - 9:00am	Hall D-E, Level 2, Washington Convention Center	Plenary Session	IComplitation and	Activity-based biomarkers for noninvasive cancer detection

<sup>\*</sup>scientist is lead author

<sup>\*\*</sup>scientist is senior author